Build Your Comparison

Side-by-side financial analysis
BLLN logo
BLLN
TMO logo
TMO
KO logo
KO
DHR logo
DHR
A logo
A
JPM logo
JPM
Try popular comparisons:

Stock Comparison

BLLN vs TMO vs KO vs DHR vs A vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
BLLN
BillionToOne, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$4.65B
5Y Perf.-1.5%
TMO
Thermo Fisher Scientific Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$174.42B
5Y Perf.+29.5%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+84.9%
DHR
Danaher Corporation

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$127.47B
5Y Perf.+14.9%
A
Agilent Technologies, Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$36.67B
5Y Perf.+46.9%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$896.00B
5Y Perf.+241.0%

BLLN vs TMO vs KO vs DHR vs A vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
BLLN logoBLLN
TMO logoTMO
KO logoKO
DHR logoDHR
A logoA
JPM logoJPM
IndustryMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchBeverages - Non-AlcoholicMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchBanks - Diversified
Market Cap$4.65B$174.42B$355.61B$127.47B$36.67B$896.00B
Revenue (TTM)$355M$45.20B$49.28B$24.78B$7.23B$280.33B
Net Income (TTM)$25M$6.86B$13.70B$3.69B$1.41B$57.05B
Gross Margin70.4%39.4%61.7%60.7%53.0%60.0%
Operating Margin10.2%17.8%29.3%21.0%21.5%25.9%
Forward P/E102.7x18.9x25.3x21.3x21.4x14.4x
Total Debt$109M$40.85B$45.49B$18.42B$3.35B$942.38B
Cash & Equiv.$496M$9.86B$10.27B$4.62B$1.79B$343.34B

BLLN vs TMO vs KO vs DHR vs A vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

BLLN
TMO
KO
DHR
A
JPM
StockJun 20Jun 26Return
Thermo Fisher Scien… (TMO)100129.5+29.5%
The Coca-Cola Compa… (KO)100184.9+84.9%
Danaher Corporation (DHR)100114.9+14.9%
Agilent Technologie… (A)100146.9+46.9%
JPMorgan Chase & Co. (JPM)100341.0+241.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: BLLN vs TMO vs KO vs DHR vs A vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: KO leads in 3 of 7 categories (6-stock set), making it the strongest pick for profitability and margin quality and dividend income and shareholder returns. JPMorgan Chase & Co. is the stronger pick specifically for valuation and capital efficiency and recent price momentum and sentiment. BLLN and DHR also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
🥇KO emerged as the overall leader. Track its performance:
BLLN
BillionToOne, Inc.
The Growth Play

BLLN ranks third and is worth considering specifically for growth exposure.

  • Rev growth 100.0%, EPS growth 106.8%
  • 100.0% revenue growth vs KO's 1.9%
Best for: growth exposure
TMO
Thermo Fisher Scientific Inc.
The Healthcare Pick

Among these 6 stocks, TMO doesn't own a clear edge in any measured category.

Best for: healthcare exposure
KO
The Coca-Cola Company
The Quality Compounder

KO carries the broadest edge in this set and is the clearest fit for quality and dividends.

  • 27.8% margin vs BLLN's 7.1%
  • 2.5% yield, 56-year raise streak, vs DHR's 0.7%, (1 stock pays no dividend)
  • 13.1% ROA vs JPM's 1.3%, ROIC 15.8% vs 4.5%
Best for: quality and dividends
DHR
Danaher Corporation
The Defensive Pick

DHR is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Lower volatility, beta 0.70, Low D/E 35.1%, current ratio 1.87x
  • Beta 0.70, yield 0.7%, current ratio 1.87x
  • Beta 0.70 vs BLLN's 1.91
Best for: sleep-well-at-night and defensive
A
Agilent Technologies, Inc.
The Healthcare Pick

A doesn't hold a clear category lead here; it's more of a secondary option in this specific comparison.

Best for: healthcare exposure
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.

  • Dividend streak 15 yrs, beta 0.94, yield 1.9%
  • 465.8% 10Y total return vs TMO's 219.0%
  • PEG 0.81 vs DHR's 35.21
  • Lower P/E (14.4x vs 21.4x), PEG 0.81 vs 1.46
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthBLLN logoBLLN100.0% revenue growth vs KO's 1.9%
ValueJPM logoJPMLower P/E (14.4x vs 21.4x), PEG 0.81 vs 1.46
Quality / MarginsKO logoKO27.8% margin vs BLLN's 7.1%
Stability / SafetyDHR logoDHRBeta 0.70 vs BLLN's 1.91
DividendsKO logoKO2.5% yield, 56-year raise streak, vs DHR's 0.7%, (1 stock pays no dividend)
Momentum (1Y)JPM logoJPM+21.8% vs DHR's -11.5%
Efficiency (ROA)KO logoKO13.1% ROA vs JPM's 1.3%, ROIC 15.8% vs 4.5%

BLLN vs TMO vs KO vs DHR vs A vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
BLLNBillionToOne, Inc.

Segment breakdown not available.

TMOThermo Fisher Scientific Inc.
FY 2025
Consumables
41.9%$18.7B
Service
41.7%$18.6B
Instruments
16.4%$7.3B
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B
DHRDanaher Corporation
FY 2025
Revenue from Contract with Customer, Measurement, Recurring
81.9%$20.1B
Revenue from Contract with Customer, Measurement, Nonrecurring
18.1%$4.4B
AAgilent Technologies, Inc.
FY 2025
Agilent CrossLab
41.9%$2.9B
Life Sciences and Applied Markets
39.2%$2.7B
Applied Markets
18.9%$1.3B
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

BLLN vs TMO vs KO vs DHR vs A vs JPM — Financial Metrics

Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKOLAGGINGA

Income & Cash Flow (Last 12 Months)

BLLN leads this category, winning 3 of 6 comparable metrics.

JPM is the larger business by revenue, generating $280.3B annually — 790.7x BLLN's $355M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to BLLN's 7.1%. On growth, BLLN holds the edge at +83.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricBLLN logoBLLNBillionToOne, Inc.TMO logoTMOThermo Fisher Sci…KO logoKOThe Coca-Cola Com…DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$355M$45.2B$49.3B$24.8B$7.2B$280.3B
EBITDAEarnings before interest/tax$44M$10.5B$15.5B$7.2B$1.8B$81.4B
Net IncomeAfter-tax profit$25M$6.9B$13.7B$3.7B$1.4B$57.0B
Free Cash FlowCash after capex$28M$6.7B$12.6B$5.3B$1.3B$100.9B
Gross MarginGross profit ÷ Revenue+70.4%+39.4%+61.7%+60.7%+53.0%+60.0%
Operating MarginEBIT ÷ Revenue+10.2%+17.8%+29.3%+21.0%+21.5%+25.9%
Net MarginNet income ÷ Revenue+7.1%+15.2%+27.8%+14.9%+19.6%+20.4%
FCF MarginFCF ÷ Revenue+7.9%+14.9%+25.5%+21.4%+17.4%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year+83.8%+6.2%+12.1%+3.7%+10.0%
EPS Growth (YoY)Latest quarter vs prior year+4.8%+11.3%+18.2%+9.8%+60.0%+16.0%
BLLN leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

JPM leads this category, winning 6 of 7 comparable metrics.

At 16.0x trailing earnings, JPM trades at a 99% valuation discount to BLLN's 1587.4x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.90x vs DHR's 35.21x — a lower PEG means you pay less per unit of expected earnings growth.

MetricBLLN logoBLLNBillionToOne, Inc.TMO logoTMOThermo Fisher Sci…KO logoKOThe Coca-Cola Com…DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…JPM logoJPMJPMorgan Chase & …
Market CapShares × price$4.7B$174.4B$355.6B$127.5B$36.7B$896.0B
Enterprise ValueMkt cap + debt − cash$4.3B$205.4B$390.8B$141.3B$38.2B$1.50T
Trailing P/EPrice ÷ TTM EPS1587.44x26.46x27.18x35.73x28.41x16.00x
Forward P/EPrice ÷ next-FY EPS est.102.72x18.88x25.27x21.34x21.43x14.40x
PEG RatioP/E ÷ EPS growth rate12.53x2.43x35.21x1.93x0.90x
EV / EBITDAEnterprise value multiple266.12x18.86x26.39x18.63x21.64x18.36x
Price / SalesMarket cap ÷ Revenue15.24x3.91x7.42x5.19x5.28x3.20x
Price / BookPrice ÷ Book value/share9.65x3.31x10.40x2.44x5.47x2.47x
Price / FCFMarket cap ÷ FCF295.98x27.72x67.15x24.23x31.83x8.88x
JPM leads this category, winning 6 of 7 comparable metrics.

Profitability & Efficiency

Evenly matched — BLLN and KO each lead in 5 of 9 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $7 for DHR. BLLN carries lower financial leverage with a 0.23x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), BLLN scores 7/9 vs JPM's 5/9, reflecting strong financial health.

MetricBLLN logoBLLNBillionToOne, Inc.TMO logoTMOThermo Fisher Sci…KO logoKOThe Coca-Cola Com…DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity+7.6%+13.2%+41.1%+7.1%+20.8%+15.9%
ROA (TTM)Return on assets+5.1%+6.4%+13.1%+4.5%+11.1%+1.3%
ROICReturn on invested capital+13.5%+7.5%+15.8%+5.9%+13.5%+4.5%
ROCEReturn on capital employed+3.7%+9.1%+17.3%+7.0%+14.5%+8.9%
Piotroski ScoreFundamental quality 0–9767755
Debt / EquityFinancial leverage0.23x0.76x1.33x0.35x0.50x2.60x
Net DebtTotal debt minus cash-$387M$31.0B$35.2B$13.8B$1.6B$599.0B
Cash & Equiv.Liquid assets$496M$9.9B$10.3B$4.6B$1.8B$343.3B
Total DebtShort + long-term debt$109M$40.9B$45.5B$18.4B$3.4B$942.4B
Interest CoverageEBIT ÷ Interest expense516.43x5.89x10.70x18.13x15.72x0.74x
Evenly matched — BLLN and KO each lead in 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

JPM leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $8,449 for DHR. Over the past 12 months, JPM leads with a +21.8% total return vs DHR's -11.5%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs DHR's -4.5% — a key indicator of consistent wealth creation.

MetricBLLN logoBLLNBillionToOne, Inc.TMO logoTMOThermo Fisher Sci…KO logoKOThe Coca-Cola Com…DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date+13.2%-20.7%+20.3%-21.7%-5.5%-0.5%
1-Year ReturnPast 12 months-7.2%+13.4%+17.2%-11.5%+10.0%+21.8%
3-Year ReturnCumulative with dividends-7.2%-9.5%+47.0%-13.0%+12.0%+138.2%
5-Year ReturnCumulative with dividends-7.2%+1.4%+65.6%-15.5%-6.9%+118.2%
10-Year ReturnCumulative with dividends-7.2%+219.0%+121.1%+222.6%+206.2%+465.8%
CAGR (3Y)Annualised 3-year return-2.5%-3.3%+13.7%-4.5%+3.8%+33.6%
JPM leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than BLLN's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs TMO's 72.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricBLLN logoBLLNBillionToOne, Inc.TMO logoTMOThermo Fisher Sci…KO logoKOThe Coca-Cola Com…DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5001.91x0.91x-0.20x0.70x1.06x0.94x
52-Week HighHighest price in past year$138.70$643.99$84.04$242.80$160.27$337.25
52-Week LowLowest price in past year$61.96$385.46$65.35$160.93$108.35$262.71
% of 52W HighCurrent price vs 52-week peak+72.9%+72.9%+98.3%+74.2%+81.0%+95.1%
RSI (14)Momentum oscillator 0–10056.550.860.652.056.159.1
Avg Volume (50D)Average daily shares traded642K2.0M12.7M4.2M1.9M7.0M
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

KO leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: BLLN as "Buy", TMO as "Buy", KO as "Buy", DHR as "Buy", A as "Buy", JPM as "Buy". Consensus price targets imply 28.7% upside for DHR (target: $232) vs 4.2% for KO (target: $86). For income investors, KO offers the higher dividend yield at 2.46% vs TMO's 0.36%.

MetricBLLN logoBLLNBillionToOne, Inc.TMO logoTMOThermo Fisher Sci…KO logoKOThe Coca-Cola Com…DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$125.00$599.70$86.13$231.80$154.75$339.75
# AnalystsCovering analysts44248434061
Dividend YieldAnnual dividend ÷ price+0.4%+2.5%+0.7%+0.8%+1.9%
Dividend StreakConsecutive years of raises8569015
Dividend / ShareAnnual DPS$1.69$2.04$1.23$0.99$5.95
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.7%+0.2%+2.4%+1.2%+3.9%
KO leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

JPM leads in 2 of 6 categories (Valuation Metrics, Total Returns). KO leads in 2 (Risk & Volatility, Analyst Outlook). 1 tied.

Best OverallThe Coca-Cola Company (KO)Leads 2 of 6 categories
Loading custom metrics...

BLLN vs TMO vs KO vs DHR vs A vs JPM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is BLLN or TMO or KO or DHR or A or JPM a better buy right now?

For growth investors, BillionToOne, Inc.

(BLLN) is the stronger pick with 100. 0% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate BillionToOne, Inc. (BLLN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — BLLN or TMO or KO or DHR or A or JPM?

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus BillionToOne, Inc. at 1587. 4x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Danaher Corporation's 35. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — BLLN or TMO or KO or DHR or A or JPM?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -15. 5% for Danaher Corporation (DHR). Over 10 years, the gap is even starker: JPM returned +465. 8% versus BLLN's -7. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — BLLN or TMO or KO or DHR or A or JPM?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus BillionToOne, Inc. 's 1. 91β — meaning BLLN is approximately -1053% more volatile than KO relative to the S&P 500. On balance sheet safety, BillionToOne, Inc. (BLLN) carries a lower debt/equity ratio of 23% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — BLLN or TMO or KO or DHR or A or JPM?

By revenue growth (latest reported year), BillionToOne, Inc.

(BLLN) is pulling ahead at 100. 0% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: BillionToOne, Inc. grew EPS 106. 8% year-over-year, compared to -4. 7% for Danaher Corporation. Over a 3-year CAGR, KO leads at 3. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — BLLN or TMO or KO or DHR or A or JPM?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus 2. 4% for BillionToOne, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus 5. 3% for BLLN. At the gross margin level — before operating expenses — BLLN leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is BLLN or TMO or KO or DHR or A or JPM more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Danaher Corporation's 35. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 102. 7x for BillionToOne, Inc. — 88. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 28. 7% to $231. 80.

08

Which pays a better dividend — BLLN or TMO or KO or DHR or A or JPM?

In this comparison, KO (2.

5% yield), JPM (1. 9% yield), A (0. 8% yield), DHR (0. 7% yield), TMO (0. 4% yield) pay a dividend. BLLN does not pay a meaningful dividend and should not be held primarily for income.

09

Is BLLN or TMO or KO or DHR or A or JPM better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). BillionToOne, Inc. (BLLN) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, BLLN: -7. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between BLLN and TMO and KO and DHR and A and JPM?

These companies operate in different sectors (BLLN (Healthcare) and TMO (Healthcare) and KO (Consumer Defensive) and DHR (Healthcare) and A (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BLLN is a small-cap high-growth stock; TMO is a mid-cap quality compounder stock; KO is a large-cap quality compounder stock; DHR is a mid-cap quality compounder stock; A is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock. KO, DHR, A, JPM pay a dividend while BLLN, TMO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.